ICAD

iCAD Among the First to Validate its AI Cancer Detection Solutions with the NVIDIA AI Enterprise Software Suite

Retrieved on: 
Mercoledì, Marzo 2, 2022
Risk, Private Securities Litigation Reform Act, Mammography, Patient, Investment, Deep learning, Hospital, Software, Breast, Woman, Donald Duck filmography, 3D, Investor, Security (finance), Breast cancer, U.S. Securities and Exchange Commission, COVID-19, Radiology, Magic: The Gathering core sets, 1993–2007, FDA, Solution, ICAD, Profound Pharma, Company, Regulation, Cancer, NASDAQ, CEO, Reading, 2D, NVIDIA, Anatomy, VMware, AI, News, Disclosure, Incidence, Algorithm, GLOBE, Medical device, Cryptocurrency, Medical imaging, Medicare

NASHUA, N.H., March 02, 2022 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it is among the first to validate its AI solutions with the NVIDIA AI Enterprise software suite .

Key Points: 
  • NASHUA, N.H., March 02, 2022 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it is among the first to validate its AI solutions with the NVIDIA AI Enterprise software suite .
  • iCADs breast health solutions help clinicians to accurately and efficiently identify cancers, categorize breast density, and assess short-term personalized breast cancer risk.
  • With NVIDIA AI Enterprise, the AI rollout process is simplified, as the software suite enables IT administrators to run and manage multiple AI applications on the same hardware, in their preferred, virtualized infrastructure.
  • Headquartered in Nashua, NH, iCAD is a global medical technology leader providing innovative cancer detection and therapy solutions.

iCAD to Present at the 42nd Annual Cowen Health Care Conference

Retrieved on: 
Martedì, Marzo 1, 2022
GLOBE, Investor, News, COVID-19, Security (finance), NASDAQ, Profound Pharma, ICAD, Company, Donald Duck filmography, Private Securities Litigation Reform Act, ICAD Inc., Regulation, U.S. Securities and Exchange Commission, Disclosure, EST, Conference, Patient, Solution, Behavior, CEO, Pharmaceutical industry, Medicare

NASHUA, N.H., March 01, 2022 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the Company will participate in the virtual 42nd Annual Cowen Health Care Conference, taking place March 7-9, 2022.

Key Points: 
  • NASHUA, N.H., March 01, 2022 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the Company will participate in the virtual 42nd Annual Cowen Health Care Conference, taking place March 7-9, 2022.
  • Stacey Stevens, President and CEO of iCAD, Inc. is scheduled to present on Tuesday, March 8, 2022, at 10:30 a.m. EST.
  • Headquartered in Nashua, NH, iCAD is a global medical technology leader providing innovative cancer detection and therapy solutions.
  • The words believe, demonstrate, intend, expect, estimate, will, continue, anticipate, likely, seek, and similar expressions identify forward-looking statements.

iCAD to Present at BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Retrieved on: 
Martedì, Febbraio 8, 2022
NASDAQ, Private Securities Litigation Reform Act, GLOBE, Disclosure, IORT, U.S. Securities and Exchange Commission, Regulation, Conference, Solution, News, Company, Investor, Digital health, ICAD, Patient, EST, Security (finance), CEO, Donald Duck filmography, Pharmaceutical industry, Medicare

NASHUA, N.H., Feb. 08, 2022 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the Company will participate in the virtual BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference from February 15-17, 2022.

Key Points: 
  • NASHUA, N.H., Feb. 08, 2022 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the Company will participate in the virtual BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference from February 15-17, 2022.
  • This is a BTIG hosted event and will not be webcast.
  • Headquartered in Nashua, NH, iCAD is a global medical technology leader providing innovative cancer detection and therapy solutions.
  • The words believe, demonstrate, intend, expect, estimate, will, continue, anticipate, likely, seek, and similar expressions identify forward-looking statements.

Intelerad Appoints Jean Boyle Vice President of Global Professional Services as Part of Ongoing Commitment to Client Delivery Excellence

Retrieved on: 
Martedì, Gennaio 25, 2022
PACS, Patient, Technology, Health, LinkedIn, Boyle, COVID-19, CEO, Solution, Industry, ICAD, Twitter, Hospital, Physician, Social media, Professional services, Medicine, KLAS, Sectra AB

In this new role, Boyle will focus on leading teams to further meet client expectations and drive satisfaction through the delivery of best-in-class medical image management and informatics solutions.

Key Points: 
  • In this new role, Boyle will focus on leading teams to further meet client expectations and drive satisfaction through the delivery of best-in-class medical image management and informatics solutions.
  • "I am elated to join Intelerad as the company continues to ramp up into its next exciting chapter for medical image management," said Boyle.
  • Bringing 20 plus years of quality assurance, solution development and deployment experience in the medical imaging industry, Boyle joins Intelerad following her role at Sectra, where she served as Vice President of Professional Services across North America for the Sweden-based company.
  • Prior to Sectra, Boyle also held VP of Professional Services roles at iCAD and Merge Healthcare, after starting her career as an MRI/X-ray technologist.

iCAD’s Breast AI Platform Earns U.S. Department of Defense Authorization to Operate

Retrieved on: 
Lunedì, Gennaio 24, 2022
Patient, Donald Duck filmography, Technology, U.S. Department of Defense Strategy for Operating in Cyberspace, MHS, Disclosure, Private Securities Litigation Reform Act, Profound Pharma, Breast cancer, NASDAQ, GLOBE, Solution, Calcification, Health, TRICARE, Investor, U.S. Securities and Exchange Commission, Ambulatory care, Malignancy, Â, RMF, ICAD, News, Company, COVID-19, Radiology, Risk, ATO, Military Health System, Regulation, DBT, Software, FDA, Family, Security (finance), Hospital, United States Department of Defense, Woman, Medical imaging, Medicare

NASHUA, N.H., Jan. 24, 2022 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that the Companys breast artificial intelligence (AI) platform was granted an Authorization to Operate (ATO) from the U.S. Department of Defense (DoD).

Key Points: 
  • NASHUA, N.H., Jan. 24, 2022 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that the Companys breast artificial intelligence (AI) platform was granted an Authorization to Operate (ATO) from the U.S. Department of Defense (DoD).
  • iCADs breast AI platform includes ProFound AI, which became the first AI software for digital breast tomosynthesis (DBT) to be FDA cleared in 2018.
  • It is a significant accomplishment for our technology to achieve this authorization, said Stacey Stevens, President and incoming Chief Executive Officer of iCAD, Inc.
  • We look forward to capitalizing on this new market opportunity and continuing to expand access to ProFound AI and enhancing patient care for those in the military and their families.

iCAD Announces the Appointment of New Members to its Board of Directors

Retrieved on: 
Martedì, Gennaio 11, 2022
Detection, National Institute for Health and Care Excellence, Patient, Donald Duck filmography, Technology, Susan, Disclosure, Adoption, CMO, Breast cancer, Senior, NASDAQ, CEO, Digital, Texas Instruments, Committee, Solution, GLOBE, National Institute, Investor, United Way Worldwide, KCL, IORT, ICAD, News, Private Securities Litigation Reform Act, Company, Regulation, NICE, Security (finance), Business school, Board, Management, Medical imaging, Director, Medicare

As previously announced, the Company also added Stacey Stevens, iCADs President and incoming CEO to the Board of Directors, bringing the total number of Board members to eight.

Key Points: 
  • As previously announced, the Company also added Stacey Stevens, iCADs President and incoming CEO to the Board of Directors, bringing the total number of Board members to eight.
  • Prior to that role, she served as Senior Vice President and Chief Digital Officer at United Way Worldwide.
  • It is an honor to join iCADs Board of Directors, and to be a part of this values-led company that is laser focused on innovation and growth.
  • Headquartered in Nashua, NH, iCAD is a global medical technology leader providing innovative cancer detection and therapy solutions.

iCAD Announces Estimated Q4 and Fiscal Year 2021 Revenues

Retrieved on: 
Martedì, Gennaio 4, 2022
Growth, COVID-19, Private Securities Litigation Reform Act, Investor, Disclosure, Software, U.S. Securities and Exchange Commission, Omicron, Dermatology, IT, Sales (accounting), GLOBE, Glioblastoma, ICAD, Company, NASDAQ, Solution, IORT, Donald Duck filmography, CEO, Regulation, Therapy, Patient, Security (finance), News, Pharmaceutical industry, Q4, Medicare

International sales continued to be sluggish throughout Q4 2021, as a result of the ongoing and re-instituted COVID-19 related restrictions in most of Europe and the rest of iCADs non-U.S. markets.

Key Points: 
  • International sales continued to be sluggish throughout Q4 2021, as a result of the ongoing and re-instituted COVID-19 related restrictions in most of Europe and the rest of iCADs non-U.S. markets.
  • We were additionally impacted by greater than 30% of our global sales team being stricken with COVID-19 in December.
  • Furthermore, the information presented herein does not present all information necessary for an understanding of the Companys year ended December 31, 2021.
  • Headquartered in Nashua, NH, iCAD is a global medical technology leader providing innovative cancer detection and therapy solutions.

iCAD to Participate at the 11th Annual LifeSci Partners Virtual Corporate Access Event

Retrieved on: 
Giovedì, Dicembre 23, 2021
Digital, CEO, Mindset, Lists of people executed in the United States, Solution, ICAD, NASDAQ, GLOBE, Chief executive officer, Industry, Pharmaceutical industry

NASHUA, N.H., Dec. 23, 2021 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD),a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will attend the 11th Annual LifeSci Partners Corporate Access Event, being held virtually from January 5th to 7th, 2022.

Key Points: 
  • NASHUA, N.H., Dec. 23, 2021 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD),a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will attend the 11th Annual LifeSci Partners Corporate Access Event, being held virtually from January 5th to 7th, 2022.
  • Stacey Stevens, President and incoming CEO of iCAD, will participate in a panel discussion titled Med Tech / Digital Tools: What's the Mindset for 2022?
  • The LifeSci Corporate Access Event will feature innovative privately held and publicly traded biotechnology, medical technology, pharmaceutical, life sciences, and digital health companies from across the globe.
  • Headquartered in Nashua, NH, iCAD is a global medical technology leader providing innovative cancer detection and therapy solutions.

First Recurrent Glioblastoma Tumor is Treated with Xoft Brain IORT in the United States

Retrieved on: 
Martedì, Dicembre 14, 2021
Anesthesia, Brain, Clinical trial, Doctor of Philosophy, Metastasis, Donald Duck filmography, ICAD, NASDAQ, Survival, Risk, EMC, Saint, Neoplasm, Disclosure, Compulsion, Solution, FDA, Radiation, Diagnosis, Regulation, Incidence, U.S. Securities and Exchange Commission, Head, Surgical Neurology International, Neuro, Security (finance), MD, GLOBE, CA, IORT, Investor, Neuroscience, GBM, Progression-free survival, CEO, Research, Associate, Surgeon, Glioblastoma, COVID, Company, Private Securities Litigation Reform Act, EBRT, Providence Saint Joseph Medical Center, News, Patient, Department, CE, Recurrence, Bevacizumab, Comparison, Translational neuroscience, Medical device, Pharmaceutical industry, Medical imaging, Medicare

NASHUA, N.H., Dec. 14, 2021 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that the first patient with recurrent glioblastoma (GBM) was treated with the Xoft® Axxent® Electronic Brachytherapy (eBx®) System® at Providence Saint John’s Health Center in Santa Monica, CA. This procedure was part of the international multi-center GLIOX triali led by principal investigator and world-renowned neuro-oncologist, Santosh Kesari, MD, PhD, Chair and Professor, Department of Translational Neurosciences at the Saint John’s Cancer Institute, Santa Monica, CA.

Key Points: 
  • The GLIOX trial is designed to compare Xoft IORT plus Avastin (bevacizumab) to the investigational arm of RTOG-1205 (EBRT plus bevacizumab).
  • Compelling data supporting Xoft Brain IORT for the treatment of recurrent GBM were recently published in study and a subsequent erratum in the peer-reviewed journal, Surgical Neurology International.
  • We feel that these initial results are encouraging, as the data indicates Xoft Brain IORT may be a viable additional treatment option for patients with recurrent GBM, added Stevens.
  • More than five patients with either brain metastases or recurrent GBM have been treated in Spain with Xoft Brain IORT since then.

iCAD to Participate at the Imagine AI + Healthcare Investor Summit

Retrieved on: 
Lunedì, Dicembre 6, 2021
Partnership, GLOBE, Solution, NASDAQ, ICAD, Medical device, Medical imaging

NASHUA, N.H., Dec. 06, 2021 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD),a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that Stacey Stevens, President and incoming Chief Executive Officer, will present a corporate overview at Oppenheimers Imagine AI + Healthcare Investor Summit being hosted by Oppenheimer in partnership with the Alliance for AI in Healthcare (AAIH).

Key Points: 
  • NASHUA, N.H., Dec. 06, 2021 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD),a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that Stacey Stevens, President and incoming Chief Executive Officer, will present a corporate overview at Oppenheimers Imagine AI + Healthcare Investor Summit being hosted by Oppenheimer in partnership with the Alliance for AI in Healthcare (AAIH).
  • Headquartered in Nashua, NH, iCAD is a global medical technology leader providing innovative cancer detection and therapy solutions.
  • For more information, visit www.icadmed.com .